SCHEMBL2831380

SCHEMBL2831380

C#CC(C)OC(=O)c1cccc(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.50
ADRB1 P08588 1/20 0.50
ADRB3 P13945 1/20 0.50
KMT2A Q03164 6/20 0.48
MEN1 O00255 4/20 0.48
CES2 O00748 2/20 0.47
CES1 P23141 2/20 0.47
ESR1 P03372 1/20 0.46
ESR2 Q92731 1/20 0.46
PARP1 P09874 1/20 0.45
PKM P14618 1/20 0.44
ALDH1A1 P00352 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
LMNA P02545 2/20 0.43
CHRNB2 P17787 1/20 0.43
SLC6A2 P23975 1/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
CHRNA4 P43681 1/20 0.43
SLC6A3 Q01959 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835316 0.84 KMT2A (0.47) ADRB2ADRB1ADRB3KMT2AMEN1
SCHEMBL12879191 0.83 RAB9A (0.49) ADRB2ADRB1ADRB3KMT2AMEN1
SCHEMBL8759589 0.82 NPC1 (0.56) ADRB2ADRB1ADRB3KMT2AMEN1
SCHEMBL30678282 0.82 NPC1 (0.56) ADRB2ADRB1ADRB3KMT2AMEN1
SCHEMBL2834996 0.81 ADRB2 (0.47) ADRB2ADRB1ADRB3KMT2AMEN1
SCHEMBL21402709 0.80 TSHR (0.53) ADRB2ADRB1ADRB3KMT2AMEN1
SCHEMBL18027643 0.80 TSHR (0.53) ADRB2ADRB1ADRB3KMT2AMEN1
SCHEMBL2834752 0.80 KMT2A (0.43) ADRB2ADRB1ADRB3KMT2AMEN1
SCHEMBL2831048 0.77 CES2 (0.49) KMT2AMEN1CES2CES1ALDH1A1
SCHEMBL2833412 0.76 ELANE (0.54) ADRB2ADRB1ADRB3KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101595082-B Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES 2013-08-21 CN disclosed
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 ADRB2 4525/4885ADRB1 4720/4885ADRB3 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.